Description
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, designed to enhance glycemic control. Clinical studies show that it can reduce HbA1c levels by up to 2% and promote weight loss, demonstrating its efficacy in managing type 2 diabetes and obesity.
For research purposes- not for human consumption
Reviews
There are no reviews yet.